Gilead Sciences, Inc. (GILD)

Gilead's stock experienced several notable events in the past six months. The company released its quarterly earnings data on Thursday, October 30th, reporting $2.47 earnings per share, beating the consensus estimate of $2.16. Revenue for the quarter was $7.77 billion, surpassing analyst estimates of $7.42 billion, and was up 3.0% compared to the same quarter last year. In early February 2026, Kite, a Gilead company, received FDA approval for an update to Yescarta's prescribing information. Gilead also announced it would release its fourth-quarter and full-year 2025 financial results on Tuesday, February 10, 2026. The stock has seen a significant increase over the past year, with a 52-week range between $93.37 and $153.13. As of February 5, 2026, the share price was $149.37, representing a 52.36% increase from February 6, 2025.

Based on the available information, there is no explicit mention of significant demand seasonality for Gilead Sciences' products and services. The company's revenue trends show consistent growth in key segments like HIV and oncology. While there was a sequential decline in liver disease sales in Q3 2024, this appears to be a short-term fluctuation rather than a clear seasonal pattern. Overall, the company's focus on chronic and life-threatening diseases suggests a relatively stable demand profile.

Gilead Sciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for unmet medical needs. Founded in 1987, it operates in the Health Technology sector, specifically Biotechnology and Drugs & Biotechnology industries. The company focuses on HIV/AIDS, liver diseases, hematology/oncology, and inflammatory and respiratory diseases, with key therapies including Biktarvy and Epclusa. Gilead expanded into oncology and cell therapy through acquisitions, offering products like Yescarta. Remdesivir (Veklury) was also authorized for treating hospitalized patients during the COVID-19 pandemic.

Gilead Sciences operates a global research and commercial organization, selling medicines in over 35 countries. The company maintains research centers and commercial operations across North America, Europe, Asia, and other regions, serving a global patient population. While U.S. revenues have shown a general upward trend from 2020 to 2024, international asset turnover has exhibited a steady and significant increase.

Gilead Sciences maintains a strong brand reputation through its commitment to advancing transformative medicines and health equity. The company is recognized as the number one funder of philanthropic HIV programs in the U.S. Recent positive events include the FDA approval of an update to Kite's Yescarta prescribing information and positive Phase 3 results for Trodelvy plus Keytruda. Gilead and the U.S. Government entered an agreement to lower medicine costs for Americans. The company has also been recognized on Forbes lists such as "America's Best Companies (2026)," "Most Trusted Companies in America (2026)," and "America's Best Employers For Company Culture (2025)."

Gilead Sciences, Inc. is predominantly owned by institutional investors, accounting for approximately 56.78% of the company's stock. Insiders own 0.08%, while public companies and individual investors own 43.13%. Major institutional shareholders include Vanguard Group Inc. and BlackRock, Inc.